| P50 | author | Nelson Hamerschlak | Q42383096 |
| | Paulo Campregher | Q57886617 |
| P2093 | author name string | Guilherme Fleury Perini | |
| | Fábio Pires de Souza Santos | |
| P2860 | cites work | Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates | Q21089989 |
| | Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain | Q24299862 |
| | Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2 | Q24306181 |
| | Cancer-associated IDH1 mutations produce 2-hydroxyglutarate | Q24320239 |
| | The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate | Q24605258 |
| | JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis | Q24609999 |
| | Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases | Q24632807 |
| | Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 | Q27687464 |
| | ASXL1 represses retinoic acid receptor-mediated transcription through associating with HP1 and LSD1 | Q28115338 |
| | The Jak-Stat pathway in normal and perturbed hematopoiesis | Q28141000 |
| | Signaling through the JAK/STAT pathway, recent advances and future challenges | Q28201804 |
| | A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera | Q28241887 |
| | The Cbl interactome and its functions | Q28277251 |
| | Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways | Q28306960 |
| | Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia | Q28585869 |
| | Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies | Q28591763 |
| | Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis | Q29614337 |
| | Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders | Q29614510 |
| | A gain-of-function mutation of JAK2 in myeloproliferative disorders | Q29618851 |
| | Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders | Q29618853 |
| | Mutation in TET2 in myeloid cancers | Q29619292 |
| | Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease | Q33839857 |
| | Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. | Q34074931 |
| | Active DNA demethylation: many roads lead to Rome. | Q34129576 |
| | Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias | Q34162729 |
| | The JAK/STAT signaling pathway | Q34305849 |
| | IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. | Q34562170 |
| | MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia | Q34770384 |
| | Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes | Q35265880 |
| | IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F | Q35835653 |
| | Transcriptional regulation and the role of diverse coactivators in animal cells | Q36024274 |
| | Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms | Q36270713 |
| | TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis | Q36303447 |
| | Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice | Q36369746 |
| | The Cbl family proteins: ring leaders in regulation of cell signaling | Q36495318 |
| | Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F | Q37232941 |
| | Roles of the EZH2 histone methyltransferase in cancer epigenetics | Q37250591 |
| | Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies | Q37701292 |
| | Rethinking disease definitions and therapeutic strategies in essential thrombocythemia and polycythemia vera | Q37829203 |
| | JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance | Q38440701 |
| | CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes. | Q39874787 |
| | Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders | Q41974528 |
| | Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations | Q42141882 |
| | Inactivation of the p53 pathway in retinoblastoma. | Q42152329 |
| | Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms | Q42795736 |
| | LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations | Q42931701 |
| | IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. | Q43089505 |
| | Mutations of ASXL1 gene in myeloproliferative neoplasms. | Q43456344 |
| | MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients | Q44008600 |
| | Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia | Q46562604 |
| | The genetic basis of myeloproliferative disorders | Q46892252 |
| | Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. | Q47956567 |
| | Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms | Q47960630 |
| | Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. | Q50528661 |
| | Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. | Q50574544 |
| | AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms. | Q50579841 |
| | Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. | Q50727065 |
| | C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells. | Q53226362 |
| | A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. | Q53312448 |
| | Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. | Q54426186 |
| | EZH2 mutational status predicts poor survival in myelofibrosis. | Q54560112 |
| | LNK mutations in JAK2 mutation-negative erythrocytosis. | Q54649906 |
| | Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. | Q55476278 |
| | BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros | Q57734316 |
| | Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance | Q58455666 |
| | JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis | Q80138604 |
| | Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival | Q80542642 |
| | Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia | Q81184235 |
| | p53 lesions in leukemic transformation | Q83352019 |
| | Another Lnk to STAT activation | Q84732116 |
| | Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms | Q95779600 |
| P433 | issue | 2 | |
| P921 | main subject | molecular biology | Q7202 |
| P304 | page(s) | 150-155 | |
| P577 | publication date | 2012-01-01 | |
| P1433 | published in | Revista brasileira de hematologia e hemoterapia | Q26842116 |
| P1476 | title | Molecular biology of Philadelphia-negative myeloproliferative neoplasms | |
| P478 | volume | 34 | |